Sangamo Therapeutics, Inc. Files 10-K/A: Key Investor Insights and Shareholder Considerations

Overview

Sangamo Therapeutics, Inc. (“Sangamo” or “the Company”) filed an amended annual report (10-K/A) for the fiscal year ended December 31, 2025. The amendment was made primarily to include information required by Part III of Form 10-K, which had previously been omitted in reliance on SEC rules allowing incorporation by reference to a proxy statement. This update is critical for investors as it provides more comprehensive disclosure about executive compensation, governance, beneficial ownership, and related matters.

Key Points from the Report

• Amendment Purpose: The 10-K/A (Amendment No. 1) is filed to include Part III disclosures, as the Company did not file its definitive proxy statement within 120 days after fiscal year-end. This includes information about directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
• Market Value and Shares Outstanding: As of June 30, 2025, the market value of Sangamo’s common stock held by non-affiliates was \$152,669,558. As of April 20, 2026, there were 414,275,509 shares of common stock outstanding.
• Company Status: Sangamo is a non-accelerated filer, a smaller reporting company, and not an emerging growth company. The company is not a shell company.
• Auditor: The Company’s independent auditor is Ernst & Young LLP, located in San Mateo, California.
• Executive Compensation: The Compensation Committee has provided detailed disclosure regarding the executive compensation program for 2025, including salary, bonuses, stock awards, and stock options for named executive officers.
• Corporate Governance: Sangamo maintains a Code of Conduct and Insider Trading Policy. Notably, directors, officers, and employees are prohibited from hedging, short-selling, margin accounts, or pledging Company securities as collateral.
• Clawback Policy: In November 2023, Sangamo adopted an incentive compensation recoupment policy (Clawback Policy) compliant with Nasdaq and SEC rules under Dodd-Frank, allowing recovery of erroneously awarded compensation from executive officers in case of restatement.
• Equity Awards and Timing: Equity awards (RSUs and stock options) are granted annually after operating plan approval and performance evaluations. Procedures are in place to prevent timing manipulation related to the release of material nonpublic information.
• Director and Committee Compensation: Detailed breakdown of annual retainers and committee chair fees, with caps on equity awards based on grant date fair value.

Potentially Price-Sensitive or Important Shareholder Information

• Delayed Proxy Statement and Comprehensive Governance Disclosure: The failure to file a definitive proxy statement within 120 days, and resulting full disclosure in the amended 10-K, could impact investor confidence regarding corporate governance and shareholder transparency.
• Executive Compensation Trends: In early 2024, the Compensation Committee decided not to increase executive base salaries due to financial constraints and capital conservation needs. This signals management’s focus on operational efficiency and cash preservation, which can affect shareholder value perceptions.
• Equity Compensation and Dilution: Equity grants are managed to minimize dilution, with target grant values based on market benchmarks. The Company intends to implement 2025 base salary increases and bonus payouts simultaneously, which may affect cash flow and dilution at the time of payment.
• Clawback Policy Implementation: The adoption of a robust clawback policy aligns Sangamo with best governance practices and strengthens investor protections against financial misstatements.
• Insider Trading Policy Stringency: Prohibition on hedging, pledging, and derivative transactions involving Company securities is stricter than many peers, potentially reducing risk and enhancing shareholder trust.
• Audit Committee and Financial Controls: The Audit Committee members are confirmed to have financial expertise, but there is no attestation by the external auditor on management’s assessment of internal controls for this amendment, as no financial statements are included.
• Compensation Recoupment and Restatement Impact: Should any future accounting restatement occur, incentive compensation could be clawed back from involved executives, which may impact executive retention and share price depending on scope.

Detailed Executive Compensation Summary (2025)

Note: Base salary increases for 2025 were approved effective January 1, 2025, but had not yet been implemented as of April 20, 2026.

Corporate Performance and Objectives

• Pipeline Progress: “Partially meets expectations” (60%) – 30 out of 40 objectives.
• Platform & Capabilities: “Mostly meets expectations” (75%) – 7.5 out of 10 objectives.
• Financial Strength: “Largely did not meet expectations” (5%) – 2.5 out of 50 objectives.

The Company is focused on advancing its prioritized pipeline, building future capabilities, and maintaining financial strength, though achievement of financial objectives was notably below expectations. This may be price sensitive as it reflects operational challenges and potential concerns about cash management and future growth.

Director Compensation and Equity Grant Policy

• Annual board retainer: \$50,000; Chair: \$35,000; Audit Committee Chair: \$20,000; Compensation Committee Chair: \$15,000; Nominating & Corporate Governance Chair: \$10,000.
• Annual equity grants (RSUs and options) are subject to aggregate limits: \$225,000 for annual grants, \$350,000 for initial grants (based on grant date fair value).
• Vesting schedules vary from monthly installments to annual tranches, contingent on continuous service.

Other Important Shareholder Information

• Communications with the Board: No formal process exists, but shareholders may communicate with directors via Investor Relations.
• Code of Conduct and ESG Disclosure: The Code of Conduct is available on Sangamo’s website and future amendments or waivers will be disclosed online.
• Audit Committee Financial Expertise: All members confirmed to meet Nasdaq standards.
• Internal Control Attestation: No auditor attestation included in this amendment.

Conclusion

The amended 10-K provides investors with updated and expanded disclosures regarding corporate governance, executive compensation, and operational performance. The lack of proxy statement filing within the required timeframe, ongoing financial constraints, and below-target achievement of key financial objectives may be considered price-sensitive developments. Investors should monitor Sangamo’s future filings, operational progress, and financial updates closely.

Disclaimer: This article summarizes key disclosures from Sangamo Therapeutics, Inc.’s 10-K/A filing for investor informational purposes only. It does not constitute investment advice. Investors should perform their own due diligence and consult professional advisors before making any investment decisions. The information herein is based on available filings and may be subject to change or further updates by the Company.

View SANGAMO THERAPEUTICS, INC Historical chart here